Alector Stock Price, News & Analysis

Alector (NASDAQ: ALEC) announced key leadership changes with Giacomo Salvadore, M.D., appointed as the new Chief Medical Officer effective April 25, 2025, replacing Gary Romano, M.D., Ph.D., who is stepping down but will continue as an advisor. Dr. Salvadore, who joined Alector in 2023 as Senior Vice President of Clinical Development, brings over 15 years of neurology-focused clinical development experience.

The company highlighted its pipeline progress, including the pivotal INFRONT-3 Phase 3 trial of latozinemab in frontotemporal dementia, with topline data expected in Q4 2025, and the PROGRESS-AD Phase 2 trial of AL101 in early Alzheimer's disease, targeting enrollment completion by mid-2025. Alector plans to advance multiple early-stage programs into IND-enabling studies later in 2025, with first-in-human trials anticipated in 2026.

Alector (NASDAQ: ALEC) reported its Q4 and full year 2024 financial results, highlighting key clinical developments and financial position. The company maintains $413.4 million in cash and investments, providing runway through 2026.

Key clinical updates include anticipated topline data from the INFRONT-3 Phase 3 trial of latozinemab in FTD-GRN by Q4 2025, and expected completion of enrollment in the PROGRESS-AD Phase 2 trial of AL101/GSK4527226 for early Alzheimer's by mid-2025.

Financial results show Q4 2024 collaboration revenue of $54.2 million, up from $15.2 million in Q4 2023. The company reported a Q4 net loss of $2.1 million ($0.02 per share), improved from $41.4 million loss in Q4 2023. For 2025, Alector projects collaboration revenue between $5-15 million, R&D expenses of $175-185 million, and G&A expenses of $55-65 million.

Alector (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract neurodegeneration, has announced its participation in three upcoming healthcare investor conferences in March 2025.

The company will deliver corporate presentations at the following events:

• TD Cowen 45th Annual Health Care Conference in Boston on Tuesday, March 4, 2025, at 9:10 a.m. ET
• Leerink Partners Global Biopharma Conference in Miami on Tuesday, March 11, 2025, at 8:40 a.m. ET
• Stifel 2025 Virtual CNS Forum on Tuesday, March 18, 2025, at 2:00 p.m. ET

Webcasts of all presentations will be available on the "Events & Presentations" page within the Investors section of the Alector website. Replay access will remain available for 90 days following each presentation.

Alector (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on neurodegeneration therapies, has scheduled its fourth quarter and full-year 2024 earnings conference call for Wednesday, February 26, 2025, at 4:30 p.m. ET/1:30 p.m. PT. The company will release its Q4 2024 financial results before the call and provide a comprehensive business update during the event.

The conference call will be accessible via webcast through Alector's investor relations website, with a 30-day replay available afterward. Phone participants must register online to receive dial-in details and a personal PIN for access.

Alector (NASDAQ: ALEC) has outlined its strategic priorities for 2025, highlighting progress in its neurodegenerative disease treatment pipeline. The company expects topline data from the INFRONT-3 Phase 3 trial of latozinemab for FTD-GRN by Q4 2025. The PROGRESS-AD Phase 2 trial of AL101/GSK4527226 for early Alzheimer's has reached 75% enrollment, with completion expected mid-2025.

The company is advancing several preclinical programs utilizing its Alector Brain Carrier (ABC) technology, including ADP037-ABC for Alzheimer's, ADP050-ABC for Parkinson's and Lewy body dementia, and tau-blocking candidates ADP063-ABC and ADP064-ABC. With $457.2 million in cash and investments as of September 30, 2024, Alector expects to fund operations through 2026.

Alector announced disappointing results from its INVOKE-2 Phase 2 trial of AL002 for early Alzheimer's disease. The drug failed to meet its primary endpoint of slowing disease progression and showed no significant effects on secondary endpoints or biomarkers. While AL002 achieved target engagement, it did not demonstrate treatment benefits and showed ARIA-related safety concerns. Following these results, Alector is discontinuing the long-term extension study and reducing its workforce by 17%. The company will focus on other programs, including the INFRONT-3 Phase 3 trial of latozinemab and PROGRESS-AD Phase 2 trial of AL101/GSK4527226. With $457.2 million in cash reserves, Alector expects runway through 2026.

Alector has secured a flexible credit facility of up to $50 million from Hercules Capital. The company drew an initial $10 million at closing, with $15 million available through June 2026 and an additional $25 million subject to lender approval. The facility carries a low double-digit cost of capital. Alector reported $457.2 million in cash and investments as of September 30, 2024, which, excluding the credit facility, is expected to fund operations through 2026. The company anticipates key data from both the AL002 INVOKE-2 Phase 2 trial and latozinemab INFRONT-3 pivotal Phase 3 trial within this runway.

Alector reported Q3 2024 financial results with collaboration revenue of $15.3 million and a net loss of $42.2 million. The company maintains a strong cash position of $457.2 million, providing runway through 2026. Key clinical updates include: the INVOKE-2 Phase 2 trial data for AL002 in early Alzheimer's disease expected in 2024, with 98% participant retention in long-term extension; INFRONT-3 Phase 3 trial for latozinemab in FTD-GRN progressing with enrollment completed; and PROGRESS-AD Phase 2 trial for AL101 reaching over one-third of target enrollment. The company reaffirmed 2024 guidance with expected collaboration revenue of $60-70 million.

Alector (Nasdaq: ALEC) presented baseline characteristics for its pivotal INFRONT-3 Phase 3 clinical trial at the 14th International Conference on Frontotemporal Dementias. The trial evaluates latozinemab, a novel monoclonal antibody, for treating frontotemporal dementia with progranulin gene mutation (FTD-GRN). Key points:

- 119 participants enrolled (103 symptomatic, 16 at-risk carriers)
- Mean age: 62.1 years
- 51.3% female, 84.9% Caucasian
- Symptomatic cohort mean CDR plus NACC FTLD-SB score: 6.9
- Mean serum neurofilament light chain: 73.0 pg/mL

The baseline characteristics suggest a representative study population, enabling effective testing of latozinemab in FTD-GRN. The trial, completed enrollment in October 2023, is ongoing with a 96-week treatment duration.